Vestipitant
Vestipitant je razvio GlaksoSmitKlajn. Ovaj lek deluje kao selektivni antagonist za NK1 receptor. On je u razvoju kao potencijalni antiemetik i anksiolitik[1][2], i kao lek za tinitus.[3]
 | |
| IUPAC ime | |
|---|---|
(2S)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methylpiperazine-1-carboxamide | |
| Identifikatori | |
| CAS broj | 334476-64-1  |
| ATC kod | none |
| PubChem | CID 9832383 |
| Hemijski podaci | |
| Formula | C23H21F10N3O |
| Molarna masa | 545.416 g/mol |
| |
Reference уреди
- ^ Reddy, GK; Gralla, RJ; Hesketh, PJ (2006). „Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis”. Supportive cancer therapy. 3 (3): 140—2. PMID 18632487. doi:10.3816/SCT.2006.n.011.
- ^ Brocco, M; Dekeyne, A; Mannoury La Cour, C; Touzard, M; Girardon, S; Veiga, S; De Nanteuil, G; Dejong, TR; Olivier, B (2008). „Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents”. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 18 (10): 729—50. PMID 18657401. doi:10.1016/j.euroneuro.2008.06.002.
- ^ Clinical Trials NCT00394056 Vestipitant Or Vestipitant/Paroxetine Combination In Subjects With Tinnitus And Hearing Loss
Vidi još уреди
Spoljašnje veze уреди
 | Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |
